TY - JOUR
T1 - Synthesis and biological activity of 4-amino-7-oxo-substituted analogoues of 5-Deaza-5,6,7,8-tetrahydrofolic acid and 5,10-dideaza-5,6,7,8- tetrahydrofolic acid
AU - Borrell, J. I.
AU - Teixido, J.
AU - Martinez-Teipel, B.
AU - Metallana, J. L.
AU - Copete, M. T.
AU - Llimargas, A.
AU - Gracia, E.
PY - 1998/8/27
Y1 - 1998/8/27
N2 - The 4-amino-7-oxo-substituted analogues of 5-deaza-5,6,7,8- tetrahydrofolic acid (5-DATHF) and 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF) were synthesized as potential antifolates. Treatment of the α,β- unsaturated esters 11a-c, obtained in one synthetic step from commercially available para-substituted benzoates (9a-c) and methyl 2-(bromomethly)- acrylate (10), with malononitrile in NaOMe/MeOH afforded the corresponding pyridones 12a-c. Formation of the pyrido[2,3-d]pyrimidines 13a-c was accomplished upon treatment of 12a-c with guanidine in methanol. After the hydrolysis of the ester group present in 13a-c, the resulting carboxylic acids 14a-c were treated with diethyl cyanophosphonate in Et3N/DMF and coupled with L-glutamic acid dimethyl ester to give 15a-c. Finally, the basic hydrolysis of 15a-c yielded the desired 4-amino-7-oxo-substituted analogues 16a-c in 20-27% overall yield. Compounds 16a-c were tested in vitro against CCRF-CEM leukemia cells. The results obtained indicated that our 4-amino-7- oxo analogues are completely devoid of any activity, the IC50 being higher than 20 μg/mL for all cases except 14c for which a value of 6.7 μg/mL was obtained. These results seem to indicate that 16a-c are inactive precisely due to the presence of the carbonyl group in position C7, the distinctive feature of our synthetic methodology.
AB - The 4-amino-7-oxo-substituted analogues of 5-deaza-5,6,7,8- tetrahydrofolic acid (5-DATHF) and 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF) were synthesized as potential antifolates. Treatment of the α,β- unsaturated esters 11a-c, obtained in one synthetic step from commercially available para-substituted benzoates (9a-c) and methyl 2-(bromomethly)- acrylate (10), with malononitrile in NaOMe/MeOH afforded the corresponding pyridones 12a-c. Formation of the pyrido[2,3-d]pyrimidines 13a-c was accomplished upon treatment of 12a-c with guanidine in methanol. After the hydrolysis of the ester group present in 13a-c, the resulting carboxylic acids 14a-c were treated with diethyl cyanophosphonate in Et3N/DMF and coupled with L-glutamic acid dimethyl ester to give 15a-c. Finally, the basic hydrolysis of 15a-c yielded the desired 4-amino-7-oxo-substituted analogues 16a-c in 20-27% overall yield. Compounds 16a-c were tested in vitro against CCRF-CEM leukemia cells. The results obtained indicated that our 4-amino-7- oxo analogues are completely devoid of any activity, the IC50 being higher than 20 μg/mL for all cases except 14c for which a value of 6.7 μg/mL was obtained. These results seem to indicate that 16a-c are inactive precisely due to the presence of the carbonyl group in position C7, the distinctive feature of our synthetic methodology.
UR - http://www.scopus.com/inward/record.url?scp=0032572817&partnerID=8YFLogxK
U2 - 10.1021/jm9801298
DO - 10.1021/jm9801298
M3 - Article
C2 - 9719607
AN - SCOPUS:0032572817
SN - 0022-2623
VL - 41
SP - 3539
EP - 3545
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 18
ER -